Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeaxanthin Alone or in Combination With Pembrolizumab in Patients With Metastatic Solid Tumors
NCT05232409Phase 1Recruiting
- Sponsor
- The Valley Health System
- Start
- Apr 2022
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of OmniXan in metastatic solid tumor (2 arms), sponsored by The Valley Health System. Primary endpoint: Safety and Tolerability at 42 days. Started Apr 2022; status: recruiting.
02
Drugs
OmniXan
03
Conditions
metastatic solid tumor
Beyond the preview
Go deeper on NCT05232409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232409.